TL;DR: Aetna modified CPB 1070 covering denileukin diftitox-cxdl (Lymphir), effective December 20, 2025. Here's what billing teams need to act on now.
Aetna updated its denileukin diftitox-cxdl coverage policy under CPB 1070, covering HCPCS code J9161 and administration codes CPT 96413–96417 and 96365–96368. The policy applies to commercial plans and sets specific stage-based medical necessity criteria for cutaneous T-cell lymphoma. If your practice or infusion center bills J9161, this policy defines exactly when Aetna will pay — and when it won't.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | Aetna |
| Policy | Denileukin Diftitox-cxdl (Lymphir) — CPB 1070 |
| Policy Code | CPB 1070 |
| Change Type | Modified |
| Effective Date | December 20, 2025 |
| Impact Level | High — precertification required on all plans |
| Specialties Affected | Hematology/Oncology, Infusion Centers, Hospital Outpatient |
| Key Action | Verify staging documentation and submit precertification before billing J9161 |
Aetna Denileukin Diftitox-cxdl Coverage Criteria and Medical Necessity Requirements 2025
The Aetna denileukin diftitox-cxdl coverage policy is tight. Aetna considers Lymphir medically necessary for one indication only: stage I–III cutaneous T-cell lymphoma (CTCL). That's it.
There is no ambiguity here. If your patient has stage IV disease, Aetna will not cover this drug under this policy. If the diagnosis is something other than CTCL — even another T-cell malignancy — Aetna treats it as experimental, investigational, or unproven.
Precertification is mandatory on all applicable Aetna commercial plan designs. This isn't optional based on plan type. Call (866) 752-7021 or fax your Statement of Medical Necessity form to (888) 267-3277 before you administer the drug. If you haven't submitted prior authorization before treatment, you're looking at a claim denial.
The prior auth covers initial therapy. Continuation of therapy requires reauthorization. Aetna will approve reauthorization when two conditions are met: the indication is still one listed in Section I of the policy (stage I–III CTCL), and there is no evidence of unacceptable toxicity or disease progression. Your clinical documentation needs to support both points explicitly.
On reimbursement: Lymphir billing runs through J9161 (injection, denileukin diftitox-cxdl, 1 mcg) for the drug itself, paired with the appropriate infusion administration code. CPT 96413 covers the first hour of chemotherapy infusion. CPT 96415 covers each additional hour. If a second drug is administered in the same encounter, CPT 96417 covers the additional sequential infusion. Make sure your charge capture maps J9161 to the right administration code — mismatches here trigger edits.
Aetna Denileukin Diftitox-cxdl Exclusions and Non-Covered Indications
Aetna's position on off-label use is unambiguous. All indications outside of stage I–III CTCL are considered experimental, investigational, or unproven. Full stop.
This matters for billing teams treating patients with subcutaneous panniculitis-like T-cell lymphoma. ICD-10 codes C86.30 and C86.31 appear in the policy's diagnosis code list — but read carefully. Those codes are listed under the "stage I–III" qualifier alongside the CTCL codes. If the documentation doesn't support stage I–III disease, you don't have coverage, even with a C86.3x code on the claim.
Any other T-cell lymphoma diagnosis, any other hematologic malignancy, any other cancer type — Aetna will deny as not medically necessary or experimental. Don't expect to appeal your way out of a denial on those. The coverage policy is explicit, and Aetna's clinical reviewers will cite this bulletin.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Cutaneous T-cell lymphoma, stage I–III | Covered | C84.A0–C84.A9, C84.AA; J9161 | Prior authorization required; precertify before treatment |
| Subcutaneous panniculitis-like T-cell lymphoma, stage I–III | Covered | C86.30, C86.31; J9161 | Stage documentation required; reauthorization needed for continuation |
| Stage IV CTCL or any other stage | Not Covered | — | Aetna considers outside stage I–III experimental/unproven |
| All other indications (any other malignancy or diagnosis) | Experimental / Not Covered | — | Policy explicitly excludes all other uses |
| Continuation of therapy (reauthorization) | Covered | J9161 | Requires no evidence of unacceptable toxicity or disease progression |
Aetna Denileukin Diftitox-cxdl Billing Guidelines and Action Items 2025
These are the steps your billing team needs to take now. The effective date is December 20, 2025 — that's already in effect.
| # | Action Item |
|---|---|
| 1 | Audit your active Lymphir patients for staging documentation. Pull every patient currently receiving denileukin diftitox-cxdl under an Aetna commercial plan. Confirm the clinical record explicitly states stage I, II, or III. If staging isn't documented clearly, work with your oncologist to update the chart before the next claim goes out. |
| 2 | Submit precertification for every new start before treatment. Call (866) 752-7021 or fax your SMN form to (888) 267-3277. Do not administer the drug before authorization is in hand. A claim denial after treatment is administered is a collections problem, not just a billing problem. |
| 3 | Update your charge capture to pair J9161 with the correct administration CPT codes. The drug is J9161. The administration is CPT 96413 for the initial chemotherapy infusion hour, 96415 for each additional hour, and 96417 for additional sequential infusions in the same encounter. For non-chemo infusion scenarios, CPT 96365 and 96366 apply. Map these correctly in your charge capture system before December 20, 2025 claims process. |
| 4 | Build a reauthorization workflow for continuation requests. Aetna requires reauthorization for ongoing therapy. Your clinical team needs to document two things at each reauth: continued stage I–III CTCL diagnosis, and no evidence of unacceptable toxicity or disease progression. Build that documentation checklist into your prior auth workflow now. |
| 5 | Flag ICD-10 codes C86.30 and C86.31 for extra review. Subcutaneous panniculitis-like T-cell lymphoma is covered — but only at stage I–III. Claims with C86.30 or C86.31 without clear staging documentation are a denial risk. Add a billing edit or pre-bill review flag for those codes on Aetna claims. |
| 6 | Check Medicare separately. CPB 1070 covers commercial plans only. Aetna directs Medicare criteria to a separate Part B resource. If you have dual-eligible patients or Medicare Advantage members, don't apply these commercial criteria. Check Aetna's Medicare Part B step therapy page directly. |
If you're billing a high volume of Lymphir across Aetna commercial members, talk to your compliance officer before the next billing cycle. The stage-specificity requirement creates real denial risk if your documentation workflow has any gaps.
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Denileukin Diftitox-cxdl Under CPB 1070
Covered HCPCS Code
| Code | Type | Description |
|---|---|---|
| J9161 | HCPCS | Injection, denileukin diftitox-cxdl, 1 mcg |
Administration CPT Codes (Related to CPB 1070)
These are the infusion administration codes associated with Lymphir delivery. Your claim needs both J9161 and the appropriate administration code.
| Code | Type | Description |
|---|---|---|
| 96413 | CPT | Chemotherapy administration, intravenous infusion — up to one hour |
| 96414 | CPT | Chemotherapy administration, intravenous infusion — each additional hour |
| 96415 | CPT | Chemotherapy administration, intravenous infusion — each additional hour |
| 96416 | CPT | Chemotherapy administration, intravenous infusion — initiation of prolonged infusion (more than 8 hours), requiring use of a portable or implantable pump |
| 96417 | CPT | Chemotherapy administration, intravenous infusion — each additional sequential infusion |
| 96365 | CPT | Intravenous infusion administration, initial up to one hour |
| 96366 | CPT | Intravenous infusion administration, each additional hour |
| 96367 | CPT | Intravenous infusion administration, additional sequential infusion, new drug/substance |
| 96368 | CPT | Intravenous infusion administration, concurrent infusion |
Key ICD-10-CM Diagnosis Codes
| Code | Description |
|---|---|
| C84.A0 | Cutaneous T-cell lymphoma, unspecified, unspecified site |
| C84.A1 | Cutaneous T-cell lymphoma, unspecified, lymph nodes of head, face, and neck |
| C84.A2 | Cutaneous T-cell lymphoma, unspecified, intrathoracic lymph nodes |
| C84.A3 | Cutaneous T-cell lymphoma, unspecified, intra-abdominal lymph nodes |
| C84.A4 | Cutaneous T-cell lymphoma, unspecified, lymph nodes of axilla and upper limb |
| C84.A5 | Cutaneous T-cell lymphoma, unspecified, lymph nodes of inguinal region and lower limb |
| C84.A6 | Cutaneous T-cell lymphoma, unspecified, intrapelvic lymph nodes |
| C84.A7 | Cutaneous T-cell lymphoma, unspecified, spleen |
| C84.A8 | Cutaneous T-cell lymphoma, unspecified, lymph nodes of multiple sites |
| C84.A9 | Cutaneous T-cell lymphoma, unspecified, extranodal and solid organ sites |
| C84.AA | Cutaneous T-cell lymphoma, unspecified, in remission |
| C86.30 | Subcutaneous panniculitis-like T-cell lymphoma, unspecified site |
| C86.31 | Subcutaneous panniculitis-like T-cell lymphoma, lymph nodes of head, face, and neck |
A note on using these codes: Aetna covers stage I–III disease. The ICD-10 system doesn't embed lymphoma staging into the code itself for most of these. Your staging documentation lives in the clinical record, not the diagnosis code. That means your claim can carry C84.A0 and still be denied if the medical record doesn't clearly establish stage. Stage documentation is your defense against denial — not just the right code.
Get the Full Picture for CPT 96413
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.